黄类衍生物的抗炎性活动
Ysrafil Ysrafil1, Zulfiayu Sapiun2, Nangsih Sulastri Slamet2
1Department of Pharmacotherapy, Faculty of Medicine, Universitas Palangka Raya, Palangka Raya 73111, Indonesia.
ADMET & DMPK
|October 13, 2023
概括
黄类药物通过阻断炎症通路,显示出抗炎潜力. 纳米技术增强了黄类药物输送,提高了新的抗炎疗法的生物可用性和疗效.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 纳米技术纳米技术
背景情况:
- 黄类,丰富的植物植物化学物质,表现出显著的抗炎性质.
- 它们的有效性与抑制炎症级联和促炎因素的产生有关.
- 低生物可用性和药理动力学对黄类药物开发构成挑战.
研究的目的:
- 审查黄类药物在缓解炎症中的作用机制.
- 讨论基于纳米技术的配送系统的潜在潜力,用于类药物.
主要方法:
- 这篇叙述性综述综合了来自in silico,in vitro,in vivo和临床研究的发现.
- 它检查了由黄类化合物调节的生化介质,酶和信号通路.
主要成果:
- 黄胺调节关键的炎症媒介,酶和信号通路.
- 纳米技术平台中的封装增强了黄酸的溶解性,生物可用性和活性.
- 纳米技术还可以减轻黄类药物的潜在毒性影响.
结论:
- 黄类药物及其衍生物显示出作为抗炎药物候选药物的前景.
- 将黄类化合物制成纳米颗粒显著提高了它们的治疗潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
173
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
173
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324
Drugs for Treatment of Ulcerative Colitis in IBD
152
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
152
Inflammatory Bowel Disease IV: Pharmacological Management
135
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
135
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
136
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
136
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
150
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
150


